MAAT PHARMA SACA (MAAT.PA) Fundamental Analysis & Valuation

EPA:MAAT • FR0012634822

Current stock price

5.49 EUR
-0.19 (-3.35%)
Last:

This MAAT.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MAAT.PA Profitability Analysis

1.1 Basic Checks

  • MAAT had negative earnings in the past year.
  • MAAT had a negative operating cash flow in the past year.
  • In the past 5 years MAAT always reported negative net income.
  • In the past 5 years MAAT always reported negative operating cash flow.
MAAT.PA Yearly Net Income VS EBIT VS OCF VS FCFMAAT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • MAAT has a Return On Assets of -69.72%. This is in the lower half of the industry: MAAT underperforms 77.38% of its industry peers.
  • MAAT has a worse Return On Equity (-1726.57%) than 71.43% of its industry peers.
Industry RankSector Rank
ROA -69.72%
ROE -1726.57%
ROIC N/A
ROA(3y)-63.57%
ROA(5y)-47.93%
ROE(3y)-700.85%
ROE(5y)-435.27%
ROIC(3y)N/A
ROIC(5y)N/A
MAAT.PA Yearly ROA, ROE, ROICMAAT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • Looking at the Gross Margin, with a value of 69.05%, MAAT is in line with its industry, outperforming 55.95% of the companies in the same industry.
  • MAAT's Gross Margin has declined in the last couple of years.
  • MAAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.27%
GM growth 5YN/A
MAAT.PA Yearly Profit, Operating, Gross MarginsMAAT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MAAT.PA Health Analysis

2.1 Basic Checks

  • MAAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MAAT has been increased compared to 1 year ago.
  • Compared to 5 years ago, MAAT has more shares outstanding
  • The debt/assets ratio for MAAT has been reduced compared to a year ago.
MAAT.PA Yearly Shares OutstandingMAAT.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
MAAT.PA Yearly Total Debt VS Total AssetsMAAT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -1.08, we must say that MAAT is in the distress zone and has some risk of bankruptcy.
  • MAAT has a Altman-Z score of -1.08. This is in the lower half of the industry: MAAT underperforms 69.05% of its industry peers.
  • A Debt/Equity ratio of 8.31 is on the high side and indicates that MAAT has dependencies on debt financing.
  • MAAT has a Debt to Equity ratio of 8.31. This is in the lower half of the industry: MAAT underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.31
Debt/FCF N/A
Altman-Z -1.08
ROIC/WACCN/A
WACC7.18%
MAAT.PA Yearly LT Debt VS Equity VS FCFMAAT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • MAAT has a Current Ratio of 1.94. This is a normal value and indicates that MAAT is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.94, MAAT is in line with its industry, outperforming 40.48% of the companies in the same industry.
  • MAAT has a Quick Ratio of 1.94. This is a normal value and indicates that MAAT is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.94, MAAT is in line with its industry, outperforming 45.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.94
MAAT.PA Yearly Current Assets VS Current LiabilitesMAAT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MAAT.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.55% over the past year.
  • Looking at the last year, MAAT shows a very strong growth in Revenue. The Revenue has grown by 40.67%.
  • The Revenue has been growing by 46.80% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.22%
Revenue 1Y (TTM)40.67%
Revenue growth 3Y46.8%
Revenue growth 5YN/A
Sales Q2Q%40.27%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.55% on average over the next years.
  • MAAT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 92.62% yearly.
EPS Next Y-3.77%
EPS Next 2Y-1.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.71%
Revenue Next 2Y25.7%
Revenue Next 3Y93.6%
Revenue Next 5Y92.62%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MAAT.PA Yearly Revenue VS EstimatesMAAT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MAAT.PA Yearly EPS VS EstimatesMAAT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. MAAT.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • MAAT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year MAAT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MAAT.PA Price Earnings VS Forward Price EarningsMAAT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MAAT.PA Per share dataMAAT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.55%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MAAT.PA Dividend Analysis

5.1 Amount

  • No dividends for MAAT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MAAT.PA Fundamentals: All Metrics, Ratios and Statistics

MAAT PHARMA SACA

EPA:MAAT (4/13/2026, 7:00:00 PM)

5.49

-0.19 (-3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)N/A
Inst Owners38.82%
Inst Owner ChangeN/A
Ins Owners1.42%
Ins Owner ChangeN/A
Market Cap103.32M
Revenue(TTM)4.52M
Net Income(TTM)-31.06M
Analysts87.27
Price Target17.27 (214.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.85%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.84
P/FCF N/A
P/OCF N/A
P/B 57.43
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0.24
BVpS0.1
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.72%
ROE -1726.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.05%
FCFM N/A
ROA(3y)-63.57%
ROA(5y)-47.93%
ROE(3y)-700.85%
ROE(5y)-435.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.27%
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 8.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.04%
Cap/Sales 13.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.94
Altman-Z -1.08
F-Score5
WACC7.18%
ROIC/WACCN/A
Cap/Depr(3y)68.34%
Cap/Depr(5y)86.38%
Cap/Sales(3y)28.64%
Cap/Sales(5y)31.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.22%
EPS Next Y-3.77%
EPS Next 2Y-1.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)40.67%
Revenue growth 3Y46.8%
Revenue growth 5YN/A
Sales Q2Q%40.27%
Revenue Next Year13.71%
Revenue Next 2Y25.7%
Revenue Next 3Y93.6%
Revenue Next 5Y92.62%
EBIT growth 1Y-3.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.68%
OCF growth 3YN/A
OCF growth 5YN/A

MAAT PHARMA SACA / MAAT.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MAAT PHARMA SACA (MAAT.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA.


What is the valuation status for MAAT stock?

ChartMill assigns a valuation rating of 0 / 10 to MAAT PHARMA SACA (MAAT.PA). This can be considered as Overvalued.


How profitable is MAAT PHARMA SACA (MAAT.PA) stock?

MAAT PHARMA SACA (MAAT.PA) has a profitability rating of 0 / 10.